BI vs SUDEEPPHRM: Stock Comparison
SUDEEP PHARMA is the larger company by market capitalisation. BI shows lower leverage, while SUDEEP PHARMA shows a higher ROE, a higher dividend yield and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BI leads 3; SUDEEPPHRM leads 6 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BI | SUDEEPPHRM |
|---|---|---|
| Live Price | ₹91.66 | ₹1,178.3 |
| Day Change | -9.59% | -1.01% |
| Volume | 10.06 L | 2.48 L |
| 52-Week High | ₹111.51 | ₹1,378 |
| 52-Week Low | ₹51.62 | ₹524.05 |
| Distance from 52W High | -17.8% | -14.49% |
Valuation
| Metric | BI | SUDEEPPHRM |
|---|---|---|
| Market Cap | ₹171 Cr | ₹13,351 Cr |
| P/E Ratio | — | 70.69x |
| P/B Ratio | — | 13.95x |
| EPS | ₹5.39 | ₹4.59 |
| Book Value | ₹31.49 | ₹79.51 |
| Dividend Yield | 0% | 0.13% |
Growth
| Metric | BI | SUDEEPPHRM |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 20.36% | 24.28% |
| Qtr Profit Growth | 90.7% | 27.65% |
Profitability & Leverage
| Metric | BI | SUDEEPPHRM |
|---|---|---|
| ROE | 0.24% | 13.69% |
| ROCE | 0.5% | 12.33% |
| Net Margin | -2.36% | 27.14% |
| Operating Margin | 31.53% | 44.66% |
| Debt to Equity | 0.03x | 0.16x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BI | SUDEEPPHRM |
|---|---|---|
| Promoter Holding | 30.01% | 76.15% |
| FII Holding | 0.04% | 2.93%▲ 1.12 pp |
| DII Holding | 0% | 14.05%▼ 1.6 pp |
| Public Holding | 69.94% | 6.87%▲ 0.48 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BI and SUDEEP PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.